{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-002932","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.397385+00:00","generated_at":"2026-06-20T18:45:53.828658+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Annexon appoints Dr. Rick Artis as Chief Scientific Officer, succeeding Dr. Larry Mattheakis","bullets":["Dean 'Rick' Artis, Ph.D., appointed CSO effective January 6, 2023, succeeding Larry C. Mattheakis who is departing.","Artis previously served as SVP of Chemistry at Annexon and discovered small molecule ANX1502.","Artis most recently was CSO at Octant Bio and has discovery-to-clinic experience across multiple therapeutic areas.","He will lead all research efforts with focus on expanding small molecule pipeline and advancing complement portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-002932","json":"https://secwatch.observer/filing/0001193125-23-002932.json","markdown":"https://secwatch.observer/filing/0001193125-23-002932.md","text":"https://secwatch.observer/filing/0001193125-23-002932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523002932/0001193125-23-002932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523002932/d426219d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:45:53.828658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89fb37d1c0","claim":"Larry C. Mattheakis departed as Chief Scientific Officer at Annexon, Inc..","evidence_excerpt":"Dr. Artis is succeeding Larry C. Mattheakis, Ph.D., who is departing from the Company and is no longer serving as Chief Scientific Officer effective as of January 6, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523002932/0001193125-23-002932-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"c25b279ea3","claim":"Dean Richard Artis was appointed as Chief Scientific Officer at Annexon, Inc..","evidence_excerpt":"the appointment of Dean Richard Artis, Ph.D. as Chief Scientific Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523002932/0001193125-23-002932-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}